Author:
Munir Anam,Akram Afia Muhammad,Jamil Khansa,Tahir Asma
Abstract
Acute myeloid leukemia (AML) refers to a diverse assemblage of hematological malignancies that constitute clonal expansion of immature myeloid progenitor cells in the peripheral blood and bone marrow. TERT gene ensures telomeres maintenance, chromosome stability and prevention of malignancy. The TERT gene has several single nucleotide polymorphisms (SNPs) that have been linked to a number of diseases, including AML. Objective: To classify the harmful TERT gene mutations, and to analyze them using various computational approaches at structural, functional and translational expression levels Methods: National Centre for Biotechnology Information (NCBI) database was used to retrieve nsSNPs of TERT gene (Q53H, V170M, A184T, S255Y, A288V, H412Y, I540M, R631W) reported in AML and they were analyzed using various bioinformatics tools. Results: In this in silico analysis, it was observed that seven out of eight SNPs had a damaging effect; they could affect the protein stability, protein-protein interactions, hydrophobicity, protein folding, three-dimensional structure, secondary structure and conservation profile. 3D models were generated and validated by various tools and the structural effect of these alterations was observed on protein function that was destabilizing to the RNA folding, protein-protein interactions and other functionally associated proteins. Analysis of post translational modifications showed no significant effect of these mutations. Conclusions: These SNPs could be used in future as potential targets in disease diagnosis, biological markers and protein studies.
Publisher
CrossLinks International Publishers
Reference38 articles.
1. Obeagu EI and Babar Q. Acute Myeloid Leukaemia (AML): The Good, the Bad, and the Ugly. International Journal of Current Research and Medical Sciences. 2021; 7(7): 29-41.
2. Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. Journal of Clinical Oncology. 2017 Mar; 35(9): 934-46. doi: 10.1200/JCO.2016.71.2208.
3. Irish W, Ryan M, Gache L, Gunnarsson C, Bell T, Shapiro M. Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse. Current Medical Research and Opinion. 2017 Mar; 33(3): 519-27. doi: 10.1080/03007995.2016.1267615.
4. Levin M, Stark M, Ofran Y, Assaraf YG. Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: Towards precision medicine overcoming drug resistance. Cancer Cell International. 2021 Dec; 21(1): 1-6. doi: 10.1186/s12935-021-01746-w.
5. Kabel A, Zamzami F, Al-Talhi M, Al-Dwila K, Hamza R. Acute myeloid leukemia: A focus on risk factors, clinical presentation, diagnosis and possible lines of management. Cancer Research Treatment. 2017; 5: 62-7.